Article thumbnail
Location of Repository

Double versus single high-dose melphalan 200 mg/m2 and autologous stem cell transplantation for multiple myeloma: a region-based study in 484 patients from the Nordic area

By Bo Björkstrand, Tobias W. Klausen, Kari Remes, Astrid Gruber, Lene M. Knudsen, Olav J. Bergmann, Stig Lenhoff and Hans E. Johnsen

Abstract

Autologous stem cell transplantation is still considered the standard of care in young patients with multiple myeloma (MM). This disease is the most common indication for high-dose therapy (HDT) supported by hematopoietic stem cell transplantation and much data support the benefit of this procedure. Results of randomized studies are in favor of tandem autologous transplantation although the effect on overall survival is unclear. Based on sequential registration trials in the Nordic area, we aimed to evaluate the outcome of conventional single or double HDT

Topics: Article
Publisher: PAGEPress Publications
OAI identifier: oai:pubmedcentral.nih.gov:3222243
Provided by: PubMed Central

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.